Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

NCT03604419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: PB-119 100 μg+ Glucophage®
DRUG: PB-119 150 μg+ Glucophage®
DRUG: PB-119 200 μg+ Glucophage®
DRUG: PB-119 placebo + Glucophage®

Sponsor

PegBio Co., Ltd.

Collaborators

[object Object]